Hormonal
Women with polycystic ovary syndrome (PCOS) exhibit an intrinsic reduction in insulin sensitivity of approximately 27% compared to controls, a deficit that persists independently of body mass index (BMI), age, or diagnostic criteria.
If you have PCOS, you likely have an intrinsic metabolic disadvantage regarding insulin sensitivity, regardless of your weight. This is not just about 'eating less' or 'exercising more' to fix a weight problem; it is a physiological trait of the syndrome. Management should focus on strategies that improve insulin sensitivity (like specific dietary patterns or medications) rather than assuming weight loss alone will normalize metabolic health.
We report an inherent reduction (−27%) of insulin sensitivity (IS) in PCOS patients, which was independent of BMI.
Why this rating
Based on a systematic review and meta-analysis of 28 gold-standard euglycaemic-hyperinsulinaemic clamp studies.
Source
Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies
Samantha Cassar et al. · Human Reproduction · 2016
DOI 10.1093/humrep/dew243
More from this paper
- Higher body mass index (BMI) exacerbates insulin resistance in women with PCOS more severely than in healthy controls, with a 10-unit increase in BMI associated with a 28% greater reduction in insulin sensitivity in PCOS compared to a 15% reduction in controls.Strong
- Low levels of sex hormone-binding globulin (SHBG) are associated with reduced insulin sensitivity in women with PCOS, independent of BMI, suggesting SHBG may serve as a useful clinical marker for insulin resistance in this population.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →